Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.
暂无分享,去创建一个
R. Baric | T. Sheahan | R. Mackman | A. Schäfer | J. Bilello | T. Cihlar | Venice Du Pont | S. Montgomery | Ariane J. Brown | R. Subramanian | D. Martinez | Joy Y. Feng | R. Bannister | D. Babusis | K. Chun | Blake J Bleier | Blake J. Bleier | E. Murakami | David R. Martinez | Jennifer Tang | Rao V. Kalla | Kimberly T. Barrett | J. Won | K. Gully | Fernando R. Moreira | D. R. Martinez | Rao V Kalla
[1] M. Marks,et al. Severe Acute Respiratory Syndrome Coronavirus 2 , 2021, Reference Module in Biomedical Sciences.
[2] M. Metzendorf,et al. Remdesivir for the treatment of COVID-19. , 2021, The Cochrane database of systematic reviews.
[3] John D. Davis,et al. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 , 2021, The New England journal of medicine.
[4] K. Gajiwala,et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.
[5] N. Bhadelia,et al. Global COVID-19 vaccine inequity: The scope, the impact, and the challenges , 2021, Cell Host & Microbe.
[6] D. Montefiori,et al. SnapShot: SARS-CoV-2 antibodies , 2021, Cell Host & Microbe.
[7] B. Haynes,et al. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice , 2021, Cell Reports.
[8] P. Cheah,et al. Vaccine hesitancy in the COVID-19 era , 2021, The Lancet Infectious Diseases.
[9] Cameron R. Wolfe,et al. Molnupiravir, an Oral Antiviral Treatment for COVID-19 , 2021, medRxiv.
[10] L. Purcell,et al. Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention , 2021, medRxiv.
[11] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[12] A. Binagwaho,et al. Time for the ethical management of COVID-19 vaccines , 2021, The Lancet Global Health.
[13] R. Mackman,et al. Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. , 2021, Journal of medicinal chemistry.
[14] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[15] D. Fremont,et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies , 2021, Nature Medicine.
[16] Lisa Rosenbaum. Escaping Catch-22 - Overcoming Covid Vaccine Hesitancy. , 2021, The New England journal of medicine.
[17] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.
[18] Lisa E. Gralinski,et al. SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801 , 2021, Nature.
[19] D. Ho,et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.
[20] P. Maassen,et al. A step backwards in the fight against global vaccine inequities , 2020, The Lancet.
[21] Samuel M. Brown,et al. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 , 2020, The New England Journal of Medicine.
[22] H. Mo,et al. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir , 2020, bioRxiv.
[23] Nguyen H. Tran,et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses , 2020, Nature Medicine.
[24] Vineet D. Menachery,et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 , 2020, Nature Communications.
[25] Lisa E. Gralinski,et al. A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice , 2020, Cell.
[26] Larissa B. Thackray,et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein , 2020, Nature Medicine.
[27] R. Baric,et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.
[28] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[29] Lisa E. Gralinski,et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract , 2020, Cell.
[30] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[31] S. Lindstrom,et al. US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.
[32] T. Liang,et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.
[33] S. Anzick,et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.
[34] Erwan L'Her,et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[35] Xiaotao Lu,et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice , 2020, Science Translational Medicine.
[36] Malik Peiris,et al. Viral dynamics in mild and severe cases of COVID-19 , 2020, The Lancet Infectious Diseases.
[37] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[38] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[39] R. Baric,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.
[40] R. Baric,et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase , 2019, Antiviral Research.
[41] Lisa E. Gralinski,et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.
[42] Ralph S. Baric,et al. A decade after SARS: strategies for controlling emerging coronaviruses , 2013, Nature Reviews Microbiology.